New Aspects in Diabetes: Treatment Strategies with Alpha-Glucosidase Inhibitors. Third International Symposium on Acarbose

List of first-mentioned contributors\nContents\nIntroduction\nI. New aspects in diabetes mellitus\nThe epidemiology of diabetes mellitus and its relationship with cardiovascular disease\nSyndrome X: fact or fiction?\nStrategies for the treatment of hyperglycemia in Syndrome X\nTreatment strategies of Syndrome X — hypertension and vascular complications\nLipid metabolism: metabolic consequences of moderate hypertriglyceridemia\nUpdate on the treatment of NIDDM\nHyperinsulinemia and macrovascular complications in NIDDM\nII. Quality of life in diabetes mellitus\nDiabetes and quality of life: some current issues in definition and research\nQuality of life in patients with type II diabetes mellitus\nWell-being in non-insulin-dependent diabetic patients (NIDDM) - a long-term follow-up\nIII. Studies with acarbose\nAcarbose monotherapy in non-insulin-dependent diabetes mellitus — the German experience\nAcarbose in non-insulin-dependent diabetes mellitus: combination with sulfonylureas and interaction with diet\nClinical efficacy of BAY g 5421 (acarbose) in noninsulin- dependent diabetes mellitus (NIDDM) — a placebo-controlled double-blind comparative study\nEffects of long-term administration of acarbose in patients with NIDDM - a double-blind study with placebo\nEffects of acarbose on blood glucose control in insulindependent diabetes mellitus\nEuropean experience in the treatment of IDDM with acarbose in combination with insulin\nRound table discussion on open questions and future aspects\nIV. Abstracts\nA multi-center, double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (BAYg 5421) in the treatment of obese patients with NIDDM treated by diet alone\nA multi-center, double-blind, placebo-controlled study of long-term efficacy and safety of acarbose (BAY g 5421) and sulfonylureas in the treatment of NIDDM inadequately controlled by maximal doses of sulfonylureas (SFU)\nA multi-center, double-blind, comparative study of the long-term efficacy and safety of acarbose (BAY g 5421) vs. placebo in the treatment of patients with insulin requiring type II diabetes mellitus\nProspective, multi-center studies of the efficacy and safety of acarbose (BAY g 5421) in the treatment of type I diabetes mellitus\nTwo multi-center, double-blind, placebo-controlled studies of efficacy and safety of acarbose treatment of type I diabetes\nClinical study of reduced postprandial hyperglycemia by acarbose and glycemic impact of fructose and sucrose in insulin therapy\n6 months monotherapy of NIDDM with acarbose or glibenclamide\nDecreased insulin requirement and postprandial insulin plasma concentrations under treatment with the a-glucosidase inhibitor acarbose\nLong-term treatment of BAY g 5421 (acarbose) in noninsulin- dependent diabetes mellitus\nClinical efficacy and tolerability of acarbose in IDDM treatment\nEffects of acarbose on the glycemic index of different foods\nEffects of acarbose on the release of gastrointestinal, pancreatic and hypophysial hormones including somatostatin in type II diabetics\nInfluence of acarbose on the release of gastrointestinal, pancreatic and hypophysial hormones including somatostatin in healthy volunteers\nAcarbose: an intestinal tract a-glucosidase inhibitor — pharmacological effects on insulin and glycemia in response to a sucrose load\nAssessment of efficacy and tolerability of acarbose (Glucobay®) by clinical data pool\nLong-term tolerability of acarbose\nAssessment of efficacy and tolerability of acarbose in diabetic patients 5 — 16 years of age\nEffect of acarbose repeated dosing on antipyrine test in healthy volunteers\nDiscussion